Research programme: antibacterials - CytoGenix

Drug Profile

Research programme: antibacterials - CytoGenix

Alternative Names: Antibacterials (multi-drug resistant) compound research programme - CytoGenix; CY 401; CY 403; CYGX 0401; Gene silencing antibacterial therapies - CytoGenix; RBL-1 research programme - CytoGenix/Imperial College London; Research programme: RBL1 - CytoGenix/Imperial College London

Latest Information Update: 02 Jun 2010

Price : $50

At a glance

  • Originator CytoGenix
  • Developer CytoGenix; Imperial College of Science, Technology and Medicine
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Bacterial infections

Most Recent Events

  • 09 Aug 2005 Preclinical trials in Bacterial infections in United Kingdom (unspecified route)
  • 09 Aug 2005 CytoGenix and Imperial College London have entered into an agreement to co-develop RBL1
  • 04 Apr 2005 CY 403 has progressed into preclinical development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top